Thermo Fisher Scientific, a world leader in serving science, signs an agreement with Suzhou New District on July 28 to establish its life sciences industry base in the district. [Photo/WeChat account: snd-szgxqfb]
Thermo Fisher Scientific, a world leader in serving science, signed an agreement with Suzhou New District on July 28 to establish its life sciences industry base in the district.
It will make an initial investment of $50 million on the industry base that will be used for establishing manufacturing centers for producing in vitro diagnostic products and biomedical products, such as in vitro diagnostic reagents, cell culture media, plastic consumables for biopharmaceuticals, and other life sciences related consumables, as well as various products customized for the Chinese market.
The industry base will be put into use in 2022, marking the company's biggest life sciences industry base in the Asia-Pacific region.
Thermo Fisher Scientific is a global top 500 company, with annual revenue exceeding $30 billion. Its China innovation centers in Shanghai and Suzhou have over 100 professional researchers, as well as more than 100 patents.
Thermo Fisher (Suzhou) Instruments Co was founded in 2011 in SND, mainly producing laboratory appliances and consumables, as well as reagents used for gene synthesis and in vitro diagnosis.
In recent years, SND has maintained an average annual growth rate of 30 percent in the high-end medical equipment and biomedicine fields. It has formed a complete industrial chain and established a platform support chain.
Home to more than 400 biomedical companies and over 370 leading talents in the field, SND achieved 20 billion yuan ($3.09 billion) in output value in 2020. It aims to add over 200 companies in the high-end medical equipment and biomedical fields per year, as well as strives to achieve 80 billion yuan in revenue in 2023.
